Lidocaine Sans Conservateur Aguettant (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. By preventing sodium influx, it stops the generation and propagation of action potentials, thereby interrupting nerve signal transmission and producing a temporary loss of pain and sensation.

The specific dose of Lidocaine Sans Conservateur Aguettant is determined by the prescribing clinician based on the intended route, patient weight, age, and the procedure being performed. Healthcare professionals calculate the appropriate volume and concentration to stay within safe maximum limits.

Safety data for lidocaine in pregnancy and lactation are limited, and the drug is generally used only when the potential benefit justifies any potential risk to the fetus or infant. Clinicians should assess each case individually and follow local guidelines regarding use in pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset (1–3 minutes) and moderate duration (1–2 hours). Compared with agents such as bupivacaine, it has a shorter duration but a lower risk of cardiotoxicity at equivalent doses, making it a common choice for short‑procedural anesthesia.

Lidocaine Sans Conservateur Aguettant should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept away from direct sunlight, moisture and extreme temperature fluctuations to maintain sterility and potency.

The product is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via epidural, infiltration or intramuscular routes. The injection technique follows standard aseptic procedures, and the volume injected is calculated according to the clinical indication and patient factors.

Serious risks include cardiac arrhythmias, seizures, methemoglobinemia and severe allergic reactions such as anaphylaxis. These events are more likely with excessive dosing, rapid intravascular injection, or in patients with pre‑existing cardiac or metabolic disorders, and require immediate medical intervention.

Lidocaine is contraindicated in patients with known hypersensitivity to amide‑type local anesthetics, those with severe heart block or uncontrolled arrhythmias, and individuals with certain metabolic disorders that predispose to methemoglobinemia. Clinicians should also exercise caution in patients with liver disease or severe renal impairment.